Zymeworks(NASDAQ) ZYME

Zymeworks Inc. creates specialized medicines for patients with difficult cancers. These treatments use protein engineering to target sick cells while protecting healthy ones. The company helps doctors treat conditions like breast, gastric, and biliary tract cancers.

The Medicine Cabinet

• Ziihera: FDA-approved bispecific antibody for treating biliary tract cancer; also in development for gastric and esophageal cancers.
• Pasritamig: Clinical-stage treatment targeting prostate cancer; engineered to engage the immune system to kill tumor cells.
• ZW191: Antibody-drug conjugate for ovarian and lung cancers; carries a toxic payload directly into cells with specific proteins.
• ZW251: Experimental drug for liver cancer; designed with properties intended to better suit patients with chronic liver disease.
• Azymetric Platform: Core technology used to build antibodies capable of binding to two different targets at the same time.

Moving the Needle

• Agreed to acquire Theravance Biopharma on June 28, 2026, to expand its portfolio and future royalty streams.
• Secured $250.0 million from Royalty Pharma in March 2026 through a loan based on future Ziihera royalties.
• Received FDA priority review in April 2026 for a new Ziihera combination treatment for gastric cancer.
• Initiated Phase 3 clinical trials for pasritamig with partner Johnson & Johnson in late 2025.
• Authorized a new $125.0 million share repurchase program on May 14, 2026.

A Different Kind of Science

Zymeworks uses structure-guided molecular modeling to design drugs that can block multiple disease pathways simultaneously. This integrated approach allows the company to share development costs with major pharmaceutical partners while retaining future royalty rights.

By the Numbers

• Total revenue was $4.6 million for the three months ended June 30, 2026, down 91% year over year.
• The company reported a net loss of $89.2 million for the six-month period ended June 30, 2026.
• Cash resources including marketable securities totaled $322.5 million as of June 30, 2026.
• The company utilized $213.6 million to repurchase common shares between Aug. 2024 and Aug. 4, 2026.

The Big Picture

Zymeworks has evolved from a pure research firm into a clinical-stage company with its first approved product and a growing royalty portfolio. Its strategy focuses on using partnership income and strategic acquisitions to fund a new generation of multifunctional therapies.